Arch Biopartners Inc (id:1259 ARCH)
1.86 CAD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 12/25/2024 9:24:18 AM)
Exchange closed, opens in 5 minutes
2.20 CAD (2.20%)
3.33 CAD (3.33%)
-7.92 CAD (-7.92%)
10.06 CAD (10.06%)
26.53 CAD (26.53%)
89.80 CAD (89.80%)
541.38 CAD (541.38%)
431.43 CAD (431.43%)
About Arch Biopartners Inc
Market Capitalization 114.95M
Arch Biopartners Inc., together with its subsidiaries, engages in the development of therapeutic drugs for inflammation and acute organ injuries in Canada. It focuses on developing its lead drug candidate LSALT Peptide, a product in Phase 2 clinical trials to treat dipeptidase-1 mediated organ inflammation in the lungs, liver, and kidneys. The company also develops AB569 for treating antibiotic-resistant bacterial infections, and for the treatment of wounds; and Borg, a peptide-solid surface interface to reduce corrosion of metals. Arch Biopartners Inc. is based in Toronto, Canada.
| Headquarters (address) |
27 Street Clair Avenue East Toronto M4T 2M5 ON Canada |
| Phone | 647 428 7031 |
| Website | https://www.archbiopartners.com |
| Employees | 0 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | ARCH |
| Exchange | Toronto Stock Exchange Venture |
| Currency | CAD |
| 52 week range | 1.36 - 2.56 |
| Market Capitalization | 114.95M |
| P/E trailing | -35.09 |
| Price/Sale | 83.08 |
| Beta | 1.39 |
| EPS | 5.00 |
| EPS Canada (ID:82, base:720) | 2.18 |